Most South African cannabis and CBD marketers are aware that SAHPRA regulates what they can claim about their products. Far fewer are aware that the ASA — the Advertising Standards Authority of South Africa — has an entirely separate and equally enforceable set of rules that governs how those products can be advertised.

The ASA Code of Advertising Practice applies to all advertising across all media in South Africa — digital, print, outdoor, broadcast, and native content. It is complaints-driven and publicly enforced. An ASA ruling against your brand is published, damages your credibility, and requires withdrawal of the offending advertising. Understanding the rules before you publish is significantly cheaper than dealing with the consequences after.

What the ASA Is and How It Works

The ASA is South Africa's self-regulatory body for advertising. It administers the Code of Advertising Practice, which sets standards for truth, accuracy, fairness, and social responsibility in advertising. The ASA does not pre-approve advertising — instead, it responds to complaints from consumers, competitors, and industry bodies.

Anyone can lodge a complaint about SA advertising with the ASA. The ASA adjudicates the complaint, and if upheld, can require the advertiser to withdraw or amend the advertising and may publish the ruling publicly. The ASA's rulings are not legally binding in the same way that court judgements are, but non-compliance has reputational and industry consequences.

ASA Rules That Apply to Cannabis and CBD Advertising

Rule 1: Substantiation of Claims

Section 4 of the ASA Code requires that all advertising claims be truthful and be capable of substantiation. For cannabis and CBD advertising, this has direct implications: any claim you make about your product's effects, benefits, or outcomes must be substantiatable with credible evidence.

The most common ASA complaints against SA CBD brands involve unsubstantiated efficacy claims: claims that CBD "reduces anxiety," "improves sleep quality," or "reduces inflammation" without supporting clinical evidence. Even soft language ("may help with") requires some level of substantiation.

The safe approach: limit claims to general wellness language that is widely understood and accepted ("promotes a sense of calm," "part of a balanced wellness routine") and avoid outcome-specific claims that require clinical substantiation.

Rule 2: Health and Safety Claims

Section 16 of the ASA Code specifically governs health and safety claims. It requires that such claims be supported by adequate and reliable scientific evidence, that they do not create undue fear or alarm, and that they do not trivialise or exploit health concerns.

For CBD brands, this means: do not make claims that your product treats, prevents, or cures any medical condition. Do not imply that using CBD is necessary for health or that not using it creates health risk. Do not use imagery or language that exploits health anxiety to sell product.

Rule 3: Comparative Advertising

The ASA permits comparative advertising but places strict conditions on it. Cannabis brands that compare their products to competitors (higher CBD content, better extraction method, superior bioavailability) must ensure these comparisons are accurate, substantiatable, and fair. False or misleading comparative claims are among the most frequently upheld ASA complaints in the wellness category.

Rule 4: Advertising to Children

The ASA Code prohibits advertising that targets children for products inappropriate for them. Cannabis and CBD products should not be advertised through channels or in formats that primarily reach under-18 audiences. This includes: advertising through children's social media accounts, using imagery or language designed to appeal to children, or advertising in media where children make up a significant portion of the audience.

Rule 5: Testimonials and Endorsements

Customer testimonials must reflect genuine, current user experiences. Testimonials that make specific health claims (even if attributed to a "real customer") are subject to the same substantiation requirements as direct brand claims. An influencer or customer saying "this CBD oil cured my anxiety" in content that your brand sponsors is your liability, not theirs.

Common ASA Violations SA Cannabis Brands Keep Making

• Unsubstantiated medical claims in product descriptions. "Our CBD oil is clinically proven to reduce anxiety" without clinical trial evidence. A complaint from a competitor or the ASA's own monitoring team will result in an upheld ruling and required withdrawal.
• Influencer posts without disclosure. The ASA requires that sponsored content (including influencer partnerships) be clearly disclosed as advertising. #ad or #sponsored is required. Failure to disclose is an ASA violation and the brand — not just the influencer — is liable.
• Before-and-after imagery implying medical outcomes. "Before CBD: anxious. After CBD: calm." This type of imagery implies a therapeutic outcome without clinical substantiation and is an ASA violation.
• FOMO-driven language exploiting health anxiety. "Don't let anxiety control your life anymore" framed around a CBD product exploits health anxiety and is non-compliant.
• Misleading "natural" or "organic" claims. Claims of being "100% natural" or "fully organic" without the certifications to support them are substantiation failures under the ASA Code.

The ASA-Compliant Cannabis Advertising Framework

Building ASA compliance into your content review process from the start is significantly easier than retrofitting compliance after a complaint. The framework:

1. Every efficacy claim must be mapped to a substantiation source before publication
2. All influencer briefs must include disclosure requirements and prohibited claim language
3. All testimonials must be verified as genuine and reviewed for medical claims before use
4. Content review should include a specific ASA compliance check in addition to SAHPRA compliance
5. Maintain a record of substantiation evidence for all published claims

For the SAHPRA compliance framework (what you can claim about your products under the Medicines Act), see our SAHPRA CBD marketing guidelines post. ASA and SAHPRA compliance are complementary — you need both.